Bourne Partners Advises Accelovance on Sale to Linical

08:00 EDT 17 Apr 2018 | Businesswire

Bourne Partners

Accelovance, Inc. (“Accelovance”), a global contract research organization (CRO) focused on oncology, vaccines and general medicine, has been acquired by Linical, a leading, Asia-based CRO providing services in the areas of oncology and central nervous system to pharmaceutical companies worldwide.

Bourne Partners, a Charlotte-based financial advisory firm focused exclusively in healthcare and life sciences, served as the sole financial advisor to Accelovance throughout the transaction. Bourne Partners also facilitated the carve-out of Accelovance’s SMO business, Optimal Research, in the fourth quarter of 2017.

Stephen Trevisan, President and Chief Executive Officer of Accelovance, said, “Bourne Partners’ experienced execution team, deep domain knowledge and extensive strategic and PE relationships were critical in maximizing the value of the sale of Accelovance. I highly recommend them as a sell-side advisor in the Clinical CRO space.”

Banks Bourne, Chief Executive Officer of Bourne Partners, said, “We are pleased to play a part in the trans-pacific connection of two leading CROs. This transaction, as well as the timely carve-out of Optimal Research, serves as a testament to the strong company Steve Trevisan and team have built over the past 13 years.”

The merger promotes a robust international presence, with the combined companies’ platform reaching through North America, Europe, and Asia Pacific.

About Accelovance

Accelovance is an award winning CRO focused on oncology, vaccine, dermatology, pain, nutrition and women’s health (Phase I-IV programs). Providing global full CRO services to pharmaceutical companies, biotechs, CROs, and academic institutions, Accelovance supports client needs by leveraging operational knowledge and patient recruitment strategies that result in successful clinical trials. Established in 2005 with a corporate mission to improve the quality and predictability in clinical research, Accelovance has made significant strides in the industry by combining strong business and operational perspective with clinical and medical expertise.

For more information, visit

About Bourne Partners

Bourne Partners is a financial services firm with over 15 years of specialized experience in the pharma, pharma services, OTC and consumer health sectors. Located in Charlotte, North Carolina, the company offers investment banking and advisory services, as well as direct investment opportunities.

For more information, visit

Bourne Partners
Lindsey Stevens, 704-552-8407


More From BioPortfolio on "Bourne Partners Advises Accelovance on Sale to Linical"

Quick Search


Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...